{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:38Z","timestamp":1761238418308},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. T315I Bcr-Abl is the most notorious point mutation to elicit acquired resistance to imatinib (IM), leading to poor prognosis. Therefore, it is urgent to search for additional approaches and targeting strategies to overcome IM resistance. We recently reported that platinum pyrithione (PtPT) potently inhibits the ubiquitin\u2013proteasome system (UPS) via targeting the 26\u2009S proteasome-associated deubiquitinases (DUBs), without effecting on the 20\u2009S proteasome. Here we further report that (i) PtPT induces apoptosis in Bcr-Abl wild-type and Bcr-Abl-T315I mutation cells including the primary mononuclear cells from CML patients clinically resistant to IM, as well as inhibits the growth of IM-resistant Bcr-Abl-T315I xenografts <jats:italic>in vivo<\/jats:italic>; (ii) PtPT downregulates Bcr-Abl level through restraining Bcr-Abl transcription, and decreasing Bcr-Abl protein mediated by DUBs inhibition-induced caspase activation; (iii) UPS inhibition is required for PtPT-induced caspase activation and cell apoptosis. These findings support that PtPT overcomes IM resistance through both Bcr-Abl-dependent and -independent mechanisms. We conclude that PtPT can be a lead compound for further drug development to overcome imatinib resistance in CML patients.<\/jats:p>","DOI":"10.1038\/cddis.2017.284","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T12:41:53Z","timestamp":1499344913000},"page":"e2913-e2913","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation"],"prefix":"10.1038","volume":"8","author":[{"given":"Xiaoying","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huidan","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"BFcddis2017284_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFcddis2017284_CR2","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ . Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808\u20134817.","journal-title":"Blood"},{"key":"BFcddis2017284_CR3","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","volume":"19","author":"NN Danial","year":"2000","unstructured":"Danial NN, Rothman P . JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000; 19: 2523\u20132531.","journal-title":"Oncogene"},{"key":"BFcddis2017284_CR4","doi-asserted-by":"publisher","first-page":"39223","DOI":"10.1074\/jbc.M007291200","volume":"275","author":"F Gesbert","year":"2000","unstructured":"Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD . BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway. J Biol Chem 2000; 275: 39223\u201339230.","journal-title":"J Biol Chem"},{"key":"BFcddis2017284_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/leu.2010.257","volume":"25","author":"H Modi","year":"2011","unstructured":"Modi H, Li L, Chu S, Rossi J, Yee JK, Bhatia R . Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia 2011; 25: 305\u2013312.","journal-title":"Leukemia"},{"key":"BFcddis2017284_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","volume":"16","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR . Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with upregulation of Bcl-xL. Oncogene 1998; 16: 1383\u20131390.","journal-title":"Oncogene"},{"key":"BFcddis2017284_CR7","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303\u20133311.","journal-title":"Blood"},{"key":"BFcddis2017284_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","volume":"40","author":"K Airiau","year":"2012","unstructured":"Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F . ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp Hematol 2012; 40: 367\u201378.e2.","journal-title":"Exp Hematol"},{"key":"BFcddis2017284_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938\u20131942.","journal-title":"Science"},{"key":"BFcddis2017284_CR10","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFcddis2017284_CR11","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFcddis2017284_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J . New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145: 913\u2013923.","journal-title":"Ann Intern Med"},{"key":"BFcddis2017284_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Brummendorf TH . Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol 2014; 11: 89\u201399.","journal-title":"Drug Discov Today Technol"},{"key":"BFcddis2017284_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75\u201385.","journal-title":"Lancet Oncol"},{"key":"BFcddis2017284_CR15","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018\u20131029.","journal-title":"Lancet Oncol"},{"issue":"1","key":"BFcddis2017284_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","volume":"2007","author":"S. Branford","year":"2007","unstructured":"Branford S . Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007: 376\u2013383.","journal-title":"Hematology"},{"key":"BFcddis2017284_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR . Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 2011; 87: 381\u2013393.","journal-title":"Eur J Haematol"},{"key":"BFcddis2017284_CR18","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFcddis2017284_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFcddis2017284_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-6-67","volume":"6","author":"P Kaur","year":"2007","unstructured":"Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V et al. Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia. Mol Cancer 2007; 6: 67.","journal-title":"Mol Cancer"},{"key":"BFcddis2017284_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol 2009; 27: 469\u2013471.","journal-title":"J Clin Oncol"},{"key":"BFcddis2017284_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-642-54490-3_5","volume":"201","author":"J Wehrle","year":"2014","unstructured":"Wehrle J, Pahl HL, von Bubnoff N . Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 2014; 201: 99\u2013107.","journal-title":"Recent Results Cancer Res"},{"key":"BFcddis2017284_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26: 428\u2013442.","journal-title":"Cancer Cell"},{"key":"BFcddis2017284_CR24","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609\u20132617.","journal-title":"N Engl J Med"},{"key":"BFcddis2017284_CR25","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","volume":"12","author":"L Zhang","year":"2013","unstructured":"Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J et al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 2013; 12: 2494\u20132504.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2017284_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrm2731","volume":"10","author":"D Komander","year":"2009","unstructured":"Komander D, Clague MJ, Urbe S . Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550\u2013563.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFcddis2017284_CR27","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/onc.2011.443","volume":"31","author":"JM Fraile","year":"2012","unstructured":"Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C . Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012; 31: 2373\u20132388.","journal-title":"Oncogene"},{"key":"BFcddis2017284_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2006-07-033209","volume":"110","author":"M Yan","year":"2007","unstructured":"Yan M, Luo JK, Ritchie KJ, Sakai I, Takeuchi K, Ren R et al. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood 2007; 110: 305\u2013312.","journal-title":"Blood"},{"key":"BFcddis2017284_CR29","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4161\/cc.8.11.8739","volume":"8","author":"S Hussain","year":"2009","unstructured":"Hussain S, Zhang Y, Galardy PJ . DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009; 8: 1688\u20131697.","journal-title":"Cell Cycle"},{"key":"BFcddis2017284_CR30","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-15-1544","volume":"75","author":"AP Lawson","year":"2015","unstructured":"Lawson AP, Long MJ, Coffey RT, Qian Y, Weerapana E, El Oualid F et al. Naturally occurring isothiocyanates exert anticancer effects by inhibiting deubiquitinating enzymes. Cancer Res 2015; 75: 5130\u20135142.","journal-title":"Cancer Res"},{"key":"BFcddis2017284_CR31","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.1074\/jbc.M112.441907","volume":"288","author":"A Peth","year":"2013","unstructured":"Peth A, Kukushkin N, Bosse M, Goldberg AL . Ubiquitinated proteins activate the proteasomal ATPases by binding to Usp14 or Uch37 homologs. J Biol Chem 2013; 288: 7781\u20137790.","journal-title":"J Biol Chem"},{"key":"BFcddis2017284_CR32","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-14-0568","volume":"20","author":"P D'Arcy","year":"2014","unstructured":"D'Arcy P, Linder S . Molecular pathways: translational potential of deubiquitinases as drug targets. Clin Cancer Res 2014; 20: 3908\u20133914.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2017284_CR33","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","volume":"115","author":"NB Heaney","year":"2010","unstructured":"Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells. Blood 2010; 115: 2241\u20132250.","journal-title":"Blood"},{"key":"BFcddis2017284_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","volume":"20","author":"X Shi","year":"2014","unstructured":"Shi X, Chen X, Li X, Lan X, Zhao C, Liu S et al. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res 2014; 20: 151\u2013163.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2017284_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bcp.2016.06.019","volume":"116","author":"C Zhao","year":"2016","unstructured":"Zhao C, Chen X, Zang D, Lan X, Liao S, Yang C et al. Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. Biochem Pharmacol 2016; 116: 22\u201338.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2017284_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.drup.2015.06.001","volume":"21-22","author":"K Selvaraju","year":"2015","unstructured":"Selvaraju K, Mazurkiewicz M, Wang X, Gullbo J, Linder S, D'Arcy P . Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors? Drug Resist Updat 2015; 21-22: 20\u201329.","journal-title":"Drug Resist Updat"},{"key":"BFcddis2017284_CR37","doi-asserted-by":"publisher","first-page":"e10510","DOI":"10.7554\/eLife.10510","volume":"4","author":"D Xu","year":"2015","unstructured":"Xu D, Shan B, Lee BH, Zhu K, Zhang T, Sun H et al. Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. Elife 2015; 4: e10510.","journal-title":"Elife"},{"key":"BFcddis2017284_CR38","doi-asserted-by":"publisher","first-page":"e1510","DOI":"10.1038\/cddis.2014.468","volume":"5","author":"C Kao","year":"2014","unstructured":"Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC et al. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis 2014; 5: e1510.","journal-title":"Cell Death Dis"},{"key":"BFcddis2017284_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajpath.2012.03.022","volume":"181","author":"T Hisatomi","year":"2012","unstructured":"Hisatomi T, Nakao S, Murakami Y, Noda K, Nakazawa T, Notomi S et al. The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization. Am J Pathol 2012; 181: 53\u201361.","journal-title":"Am J Pathol"},{"key":"BFcddis2017284_CR40","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/hmg\/ddi312","volume":"14","author":"V Menendez-Benito","year":"2005","unstructured":"Menendez-Benito V, Verhoef LG, Masucci MG, Dantuma NP . Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet 2005; 14: 2787\u20132799.","journal-title":"Hum Mol Genet"},{"key":"BFcddis2017284_CR41","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","volume":"15","author":"X Shi","year":"2009","unstructured":"Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15: 1686\u20131697.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2017284_CR42","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","volume":"118","author":"T O'Hare","year":"2011","unstructured":"O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H et al. The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 2011; 118: 5250\u20135254.","journal-title":"Blood"},{"key":"BFcddis2017284_CR43","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.18632\/oncotarget.6425","volume":"7","author":"H Huang","year":"2016","unstructured":"Huang H, Liao Y, Liu N, Hua X, Cai J, Yang C et al. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget 2016; 7: 2796\u20132808.","journal-title":"Oncotarget"},{"key":"BFcddis2017284_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 1986; 233: 212\u2013214.","journal-title":"Science"},{"key":"BFcddis2017284_CR45","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.18632\/oncotarget.2361","volume":"5","author":"X Chen","year":"2014","unstructured":"Chen X, Shi X, Zhao C, Li X, Lan X, Liu S et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms. Oncotarget 2014; 5: 9118\u20139132.","journal-title":"Oncotarget"},{"key":"BFcddis2017284_CR46","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/1535-7163.MCT-09-0386","volume":"8","author":"DH Mak","year":"2009","unstructured":"Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009; 8: 2509\u20132516.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2017284_CR47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","volume":"107","author":"BZ Carter","year":"2006","unstructured":"Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al. Regulation of survivin expression through Bcr-Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006; 107: 1555\u20131563.","journal-title":"Blood"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2017284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cddis.2017.284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T18:13:50Z","timestamp":1671732830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2017284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["BFcddis2017284"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2017.284","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]},"assertion":[{"value":"4 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}